BRIEF-Puma Biotech applies for marketing approval for breast cancer drug
July 21, 2016 at 17:37 PM EDT
* Submits NDA for PB272 (neratinib) to U.S. FDA for extended adjuvant treatment of HER2-positive early stage breast cancer Source text for Eikon: Further company coverage:
